Deka Bank Deutsche Girozentrale Chemo Centryx, Inc. Transaction History

Deka Bank Deutsche Girozentrale

$53.9 Billion
Q3 2024

Shares

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2022 Apr 28, 2022	BUY	$22.22 - $39.12 $62,216 - $109,536	2,800 Added 10.04%	30,700 $768,000
Q4 2021 Feb 02, 2022	BUY	$18.38 - $40.5 $14,704 - $32,400	800 Added 2.95%	27,900 $995,000
Q4 2020 Mar 12, 2021	BUY	$47.25 - $65.16 $500,850 - $690,696	10,600 Added 64.24%	27,100 $1.64 Million
Q3 2020 Oct 29, 2020	BUY	$46.35 - $61.69 $764,775 - $1.02 Million	16,500 New	16,500 $868,000
Q4 2019 Feb 04, 2020	SELL	$6.81 - $39.55 $112,365 - $652,575	-16,500 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$6.47 - $8.96 $106,755 - $147,840	-16,500 Reduced 50.0%	16,500 $108,000
Q2 2019 Aug 01, 2019	BUY	$8.31 - $14.85 $108,030 - $193,050	13,000 Added 65.0%	33,000 $295,000
Q1 2019 May 10, 2019	BUY	$10.01 - $13.89 $35,035 - $48,615	3,500 Added 21.21%	20,000 $259,000
Q4 2018 Feb 12, 2019	SELL	$9.15 - $12.26 $32,025 - $42,910	-3,500 Reduced 17.5%	16,500 $173,000
Q1 2018 May 03, 2018	BUY	$5.9 - $14.99 $118,000 - $299,800	20,000 New	20,000 $280,000

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deka Bank Deutsche Girozentrale, based on Form 13F filings with the SEC.

News

Stay updated on Deka Bank Deutsche Girozentrale with notifications on news.